

Resource Summary Report

Generated by SPARC SAWG on Jul 29, 2026

Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility

RRID:SCR_023479

Type: Tool

Proper Citation

Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility (RRID:SCR_023479)

Resource Information

URL: <https://cancer.dartmouth.edu/scientists-researchers/pathology-shared-resource>

Proper Citation: Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility (RRID:SCR_023479)

Description: Facilitates project planning, clinical validation and implementation of novel translational technology and research in fields of molecular diagnostics, molecular therapeutics, pharmacogenomics, quantitative morphologic image analysis and immunohistochemistry in CLIA-certified, CAP-accredited laboratory ensuring optimal clinical quality assurance.

Synonyms: DH Pathology Shared Resource, Geisel School of Medicine at Dartmouth DH Pathology Shared Resource

Resource Type: access service resource, service resource, core facility

Keywords: USEDit, ABRF, project planning, clinical validation and implementation of novel translational technology, molecular diagnostics, molecular therapeutics, pharmacogenomics, quantitative morphologic image analysis, immunohistochemistry

Resource Name: Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility

Resource ID: SCR_023479

Alternate IDs: ABRF_1731

Alternate URLs: <https://coremarketplace.org/?FacilityID=1731&citation=1>

Record Creation Time: 20230419T050215+0000

Record Last Update: 20260729T044556+0000

Ratings and Alerts

No rating or validation information has been found for Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility.

No alerts have been found for Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Robins SM, et al. (2025) Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review. Journal of neuropathology and experimental neurology, 84(5), 379.

Johnson AL, et al. (2025) Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast Cancer. Cancers, 17(12).

Jakubzick C, et al. (2025) The Dichotomy of Tumor Control by Recruited and Resident Tumor-Associated Macrophages. Research square.

Tau S, et al. (2025) Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosis. bioRxiv : the preprint server for biology.

Ronen S, et al. (2025) Cribriform Tumor of the Skin: Identification of 6q and 9q Loss as a Recurrent Cytogenomic Alteration. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 39(1), 100916.

Friedman BJ, et al. (2025) Sclerosing melanocytic tumors with MAP2K1 in frame deletions and 15q gains: A distinctive pathway of nevogenesis with reproducible morphology. Virchows Archiv : an international journal of pathology.

Tau S, et al. (2025) Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. Cancer research, 85(6), 1145.

Costa FD, et al. (2025) Pineal region high-grade neuroepithelial tumors with NTRK fusions map to the novel methylation class "diffuse high-grade glioma, IDH-wild type, subtype E". Acta neuropathologica, 150(1), 26.

Jones VM, et al. (2024) Angiomyolipomatous Lesions of the Nasal Cavity (Sinonasal Angioleiomyoma with Adipocytic Differentiation): A Multi-Institutional Immunohistochemical and Molecular Study. Research square.

Bentz JL, et al. (2024) High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases (Basel, Switzerland), 12(8).

Bagheri M, et al. (2024) Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer. Epigenomics, 16(5), 293.

Tau S, et al. (2024) Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation. bioRxiv : the preprint server for biology.

Jones VM, et al. (2024) Angiomyolipomatous Lesions of the Nasal Cavity (Sinonasal Angioleiomyoma with Adipocytic Differentiation): A Multi-Institutional Immunohistochemical and Molecular Study. Head and neck pathology, 18(1), 93.

Schwartz GN, et al. (2023) Alternating 17 β -Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(15), 2767.

Traphagen NA, et al. (2023) Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(18), 3717.